Physician profile
Sarah E Smith
NPI 1861635666
$7,179.14
in general payments reported to CMS, 2019-2025
56 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,540 · 2022: $1,024 · 2023: $935 · 2024: $1,572 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,615.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.84 | 2021-2025 | |
| Pfizer INC. | $579.03 | 2021-2025 | |
| Lundbeck LLC | $333.24 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $311.61 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Allergan, INC. | $302.46 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $256.70 | 2024-2025 | Ponvory |
| Amgen INC. | $248.38 | 2021-2025 | Aimovig |
| Alexion Pharmaceuticals, INC. | $231.79 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $207.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $192.05 | 2021-2025 | |
| Emd Serono, INC. | $181.18 | 2024-2025 | Mavenclad |
| Sk Life Science, INC. | $163.73 | 2021-2025 | |
| Ucb, INC. | $158.00 | 2021-2025 | Rystiggo, Zilbrysq, Fintepla |
| Neurocrine Biosciences, INC. | $153.94 | 2021 | |
| Axsome Therapeutics, INC. | $151.58 | 2025 | Symbravo |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.